1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (011) 852-28199636
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma
Article first published online: 23 JUN 2009
DOI: 10.1002/cncr.24495
Copyright © 2009 American Cancer Society
Additional Information
How to Cite
Xu, M. Z., Yao, T.-J., Lee, N. P. Y., Ng, I. O. L., Chan, Y.-T., Zender, L., Lowe, S. W., Poon, R. T. P. and Luk, J. M. (2009), Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer, 115: 4576–4585. doi: 10.1002/cncr.24495
Publication History
- Issue published online: 17 SEP 2009
- Article first published online: 23 JUN 2009
- Manuscript Accepted: 13 FEB 2009
- Manuscript Revised: 22 JAN 2009
- Manuscript Received: 1 DEC 2008
Funded by
- Research Grants Council of Hong Kong. Grant Numbers: 772109M, 771607M
- Innovation and Technology Commission of the Hong Kong Government. Grant Number: ITS120/07
- Sun Chieh Yeh Research Foundation for Hepatobiliary and Pancreatic Surgery
References
- 1, , . Patterns of cancer incidence, mortality, and prevalence across 5 continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24: 2137-2150.
- 2, , , et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 10-30.Direct Link:
- 3, . Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004; 127( 5 suppl 1): S72-S78.
- 4. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002; 35( 5 suppl 2): S72-S781.
- 5, , , , , . Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.Direct Link:
- 6, , , et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007; 141: 330-339.
- 7, , , et al. Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma. Surgery. 2002; 131( 1 suppl): S148-S152.
- 8, , , et al. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg. 2006; 192: 29-33.
- 9, . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43( 2 suppl 1): S99-S112.Direct Link:
- 10, . Liver cancer: the role of stem cells. Cell Prolif. 2005; 38: 407-421.Direct Link:
- 11, , , et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006; 125: 1253-1267.
- 12, , , et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 2006; 103: 12405-12410.
- 13, , , et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007; 21: 2747-2761.
- 14, , , et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008; 22: 1962-1971.
- 15, , , et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol. 2006; 26: 77-87.
- 16, , , et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130: 1120-1133.
- 17, . How size is controlled: from Hippos to Yorkies. Nat Cell Biol. 2007; 9: 1225-1227.
- 18, . Size control goes global. Curr Opin Biotechnol. 2007; 18: 341-350.
- 19. Hippo signaling in organ size control. Genes Dev. 2007; 21: 886-897.
- 20, . Fat flies expanded the hippo pathway: a matter of size control. Sci STKE. 2007( 380): pe12.
- 21, , , . Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg. 2000; 231: 544-551.
- 22, , , et al. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics. 2008; 7: 315-325.
- 23, , , , , . Identification of liver-intestine cadherin in hepatocellular carcinoma—a potential disease marker. Biochem Biophys Res Commun. 2003; 311: 618-624.
- 24, , , , . Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 2003; 63: 3121-3126.
- 25, , , , , . Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin Cancer Res. 2005; 11( 2 pt 1): 483-489.
- 26, . Signaling mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of tyrosine phosphorylation. Biochem Biophys Res Commun. 1997; 236: 479-482.
- 27, , , et al. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics. 2006; 6: 1049-1057.Direct Link:
- 28, , , , , . Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol. 2000; 18: 1094-1101.
- 29
- 30, , , , , . Biology of hepatocellular carcinoma. Ann Surg Oncol. 2008; 15: 962-971.
- 31, , , et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38: 200-207.
- 32, , , et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007; 17: 2054-2060.
- 33, , , , . Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem. 2008; 283: 5496-5509.
- 34, . Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin Liver Dis. 1999; 19: 287-296.
- 35, , , et al. Liver resection for hepatocellular carcinoma: a multivariate analysis of factors associated with improved prognosis. The role of clinical, pathological and surgical related factors. Tumori. 2007; 93: 264-268.
- 36, , , , . Morphology and other prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med. 1999; 123: 524-528.
- 37, , , , . Prognostic factors in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection. J Gastroenterol Hepatol. 2002; 17: 1205-1210.Direct Link:
- 38, , , et al. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 2007; 120: 2650-2655.Direct Link: